Leading up to the publication of the Evaluate Vantage 2022 Preview, we created this Infographic to provide a snapshot of the products and companies that are driving top line growth in the biopharma sector, key financial market trends, and the challenges and opportunities that lie ahead.
Leading up to the publication of the Evaluate Vantage 2022 Preview, we created this Infographic to provide a snapshot of the products and companies that are driving top line growth in the biopharma sector, key financial market trends, and the challenges and opportunities that lie ahead.
This article pack, produced by Evaluate Vantage’s team of award-winning journalists, presents expert analysis and insights on data recently presented at the 63rd annual…
This article pack, produced by Evaluate Vantage’s team of award-winning journalists, presents expert analysis and insights on data recently presented at the 63rd annual…
Covid-19 will still be a front-page story in 2022, keeping the biopharma sector in the spotlight. The attention will bring some benefits, largely in the shape of broad…
Covid-19 will still be a front-page story in 2022, keeping the biopharma sector in the spotlight. The attention will bring some benefits, largely in the shape of broad…
After a bruising 2021, biotech investors are hoping for a rebound. We interviewed investors and biopharma participants from across the sector, asking them to share their…
After a bruising 2021, biotech investors are hoping for a rebound. We interviewed investors and biopharma participants from across the sector, asking them to share their…
Special purpose acquisition companies, known as Spacs or “blank check companies”, are not new but have recently rocketed in popularity as a vehicle for going public…
The year-end oncology congress season kicked off with the annual IASLC World Conference on Lung Cancer. While it took place in virtual format from September 8-14, this…
Conducted as a virtual event from 16 to 21 September, ESMO 2021 brought together an international community of experts across disciplines. Once again, this oncology…
